Who is sponsoring NCT00089219?

NCT00089219 is sponsored by University of Virginia.

What condition does NCT00089219 study?

NCT00089219 studies Intraocular Melanoma, Melanoma (Skin).

What drugs are being tested in NCT00089219?

Interventions: IFA, 6MHP, GM-CSF.

What is the status of NCT00089219?

NCT00089219 is currently COMPLETED.

Last reviewed 2014-11-18 · How we verify

Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma

NCT00089219 Phase 1/Phase 2 COMPLETED

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating patients with stage IIIB, stage IIIC, or stage IV melanoma.

Details

Lead sponsor	University of Virginia
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	39
Start date	2003-07

Conditions

Intraocular Melanoma
Melanoma (Skin)

Interventions

IFA
6MHP
GM-CSF

Primary outcomes

Safety: Dose-limiting toxicity — During study period
Toxicities measured by CTCAE.
Immunogenicity — day 22
Melanoma peptide-specific helper T cell responses in the sentinel immunized node (SIN) on day 22.

Countries

United States